Poolbeg Pharma (LON:POLB) Stock Price Down 2.5% – What’s Next?
by Doug Wharley · The Cerbat GemPoolbeg Pharma PLC (LON:POLB – Get Free Report) dropped 2.5% during trading on Tuesday . The stock traded as low as GBX 3.90 and last traded at GBX 3.90. Approximately 384,483 shares were traded during trading, a decline of 79% from the average daily volume of 1,804,502 shares. The stock had previously closed at GBX 4.
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a “house stock” rating on shares of Poolbeg Pharma in a report on Thursday, November 20th.
View Our Latest Research Report on POLB
Poolbeg Pharma Stock Performance
The firm has a market cap of £27.89 million, a price-to-earnings ratio of -3.51 and a beta of 2.11. The business’s 50 day moving average price is GBX 3.85 and its 200 day moving average price is GBX 3.51.
Poolbeg Pharma (LON:POLB – Get Free Report) last posted its earnings results on Monday, September 29th. The company reported GBX (0.43) earnings per share (EPS) for the quarter. Sell-side analysts anticipate that Poolbeg Pharma PLC will post -0.68 earnings per share for the current fiscal year.
About Poolbeg Pharma
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.